- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Roger Kathol, MD, Discusses the Evolving Role Of Psychiatry In The Era Of Healthcare Reform
Roger Kathol, MD, president of Cartesian Solutions, Inc, and professor of internal medicine and psychiatry at the University of Minnesota, says that health reform presents several opportunities for psychiatrists.
Roger Kathol, MD, president of Cartesian Solutions, Inc, and professor of internal medicine and psychiatry at the University of Minnesota, says that health reform presents several opportunities for psychiatrists. Currently, most psychiatrists practice in stand-alone behavioral health settings. He says most will shift to providing services in medical settings such as accountable care organizations (ACOs).
“Because the Affordable Care Act set the stage for ACOs being able to contract for provider services in completely different ways than they have in the past, then the psychiatrist can be paid through medical benefits and then they can deliver services—and make a living wage in doing so—in the outpatient, inpatient, and post-acute settings,” says Dr Kathol.
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Closing the Gaps in Cardiac Care With Technology, Collaboration
March 12th 2025Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.
Read More
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
